{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response (CR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Complete Response (CR): Disappearance of all target lesions.\n\nPartial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.","groups":[{"description":"Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All 34 participants were evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"From study enrollment to the first date of disease progression","title":"Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.","type":"SECONDARY","unitOfMeasure":"participants"}